Linked Life Data

15723967

Source:http://linkedlifedata.com/resource/pubmed/id/15723967

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
4
pubmed:dateCreated
2005-3-25
pubmed:abstractText
The present study explored the possibility that estrogen enhances the inhibitory effect of an angiotensin II type-1 (AT1) receptor blocker (ARB), olmesartan, on atherosclerosis, focusing on oxidative stress using apolipoprotein E knockout mice (ApoEKO). After 6 weeks on a high-cholesterol diet, marked atherosclerotic lesion formation with an increase in oxidative stress, such as superoxide production, NAD(P)H oxidase activity and expression of p47phox mRNA and rac-1 mRNA, were observed in the proximal aorta in both male and female ApoEKO mice, whereas these changes were less marked in female mice. Ovariectomy enhanced these parameters, the changes of which were reversed by 17beta-estradiol (80 microg/kg per day) replacement. Treatment with olmesartan (3 mg/kg per day) significantly inhibited oxidative stress and atherosclerosis, whereas its inhibitory effects were more marked in female than in male or ovariectomized mice. Smaller doses of olmesartan (0.5 mg/kg per day) or 17beta-estradiol (20 microg/kg per day) did not influence atherosclerosis and oxidative stress in ovariectomized mice, whereas co-administration of olmesartan and 17beta-estradiol at these doses attenuated these parameters. An angiotensin-converting enzyme (ACE) inhibitor, temocapril, also inhibited atherosclerotic changes similarly to olmesartan. Moreover, angiotensin II-mediated activation of NAD(P)H oxidase in cultured vascular smooth muscle cells was attenuated by 17beta-estradiol. These results indicate that estrogen and an ARB synergistically attenuate atherosclerosis at least partly via inhibition of oxidative stress.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Apr
pubmed:issn
1524-4563
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
45
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
545-51
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed-meshheading:15723967-Angiotensin II, pubmed-meshheading:15723967-Angiotensin II Type 1 Receptor Blockers, pubmed-meshheading:15723967-Animals, pubmed-meshheading:15723967-Apolipoproteins E, pubmed-meshheading:15723967-Arteriosclerosis, pubmed-meshheading:15723967-Cells, Cultured, pubmed-meshheading:15723967-Enzyme Activation, pubmed-meshheading:15723967-Estradiol, pubmed-meshheading:15723967-Female, pubmed-meshheading:15723967-Imidazoles, pubmed-meshheading:15723967-Male, pubmed-meshheading:15723967-Mice, pubmed-meshheading:15723967-Mice, Knockout, pubmed-meshheading:15723967-Muscle, Smooth, Vascular, pubmed-meshheading:15723967-Myocytes, Smooth Muscle, pubmed-meshheading:15723967-NADPH Oxidase, pubmed-meshheading:15723967-Ovariectomy, pubmed-meshheading:15723967-Oxidative Stress, pubmed-meshheading:15723967-Tetrazoles
pubmed:year
2005
pubmed:articleTitle
Inhibitory effects of AT1 receptor blocker, olmesartan, and estrogen on atherosclerosis via anti-oxidative stress.
pubmed:affiliation
Department of Molecular and Cellular Biology, Ehime University School of Medicine, Shigenobu, Ehime, Japan.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't